Literature DB >> 7493293

Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.

M D Weltman1, A Brotodihardjo, E B Crewe, G C Farrell, M Bilous, J M Grierson, C Liddle.   

Abstract

Chronic coinfection with the hepatitis B (HBV) and hepatitis delta (HDV) viruses is known to cause severe liver disease, but the importance of coinfection with hepatitis C virus (HCV) and HBV has not been well documented. In the present study, the clinical and pathological severity of liver disease among patients with hepatitis resulting from multiple viruses was examined and an open trial of the efficacy of interferon-alpha 2b (IFN-alpha) treatment was conducted. Nineteen patients with chronic HBV and HCV infection and 17 with HBV, HCV and HDV infection were studied; 12 in each group underwent liver biopsy. For each coinfected patient, two patients infected with HCV alone were selected as controls, and these were matched for age and risk factor and were estimated to have been infected for a similar duration. Coinfection with HBV and HCV or HBV, HCV and HDV was associated with more severe liver disease than HCV alone (P < 0.01); total Scheuer score, portal and lobular inflammation and fibrosis were all worse in coinfected subjects. Eight patients with chronic HBV and HCV were treated with recombinant IFN-alpha 2b [3 million units (MU), thrice weekly for 6 months]. Liver function tests normalized in two patients and one lost hepatitis B surface antigen (HBsAg). Seven patients with hepatitis B, C and delta coinfection were treated with the same regimen and only one normalized serum alanine aminotransferase (ALT) during (and after) treatment. It is concluded that coinfection with multiple hepatitis viruses is associated with histologically more severe liver disease than HCV alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493293     DOI: 10.1111/j.1365-2893.1995.tb00070.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  26 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  Hepatitis B.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

Review 3.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 4.  Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.

Authors:  Xian-Wan Jiang; Jian-Zhong Ye; Ya-Ting Li; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 5.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 6.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

7.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

8.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

9.  Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

Authors:  Junichi Tazawa; Manabu Maeda; Mina Nakagawa; Hideo Ohbayashi; Fumihiko Kusano; Michio Yamane; Yoshinori Sakai; Keiko Suzuki
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

Review 10.  Hepatitis C treatment: current and future perspectives.

Authors:  Saira Munir; Sana Saleem; Muhammad Idrees; Aaliyah Tariq; Sadia Butt; Bisma Rauff; Abrar Hussain; Sadaf Badar; Mahrukh Naudhani; Zareen Fatima; Muhmmad Ali; Liaqat Ali; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Zunaira Awan
Journal:  Virol J       Date:  2010-11-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.